The Securities and Exchange Commission (SEC) charged Robert Gadimian, erstwhile senior director of regulatory affairs with insider trading ahead of the company�s announcement about its treatment to cure breast cancer. The regulator alleged that Gadimian made more than $1.1mn by surreptitiously buying Puma stock $PBYI and short-term call options based on nonpublic information he received which showed positive developments in two clinical trials for the treatment, neratinib.